article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

article thumbnail

8 famous people you didn’t know were cannabis patients

The Cannigma

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

European Regulatory Lead MAPS PBC Santa Cruz, CA

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary. Key Responsibilities.

article thumbnail

Missouri Republican,Michael Davis, proposes adding access to LSD, MDMA, peyote, and psilocybin as treatment options

Cannabis Law Report

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Right-to-try permits those patients to have access to investigational drugs.

article thumbnail

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Cannabis Law Report

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52
article thumbnail

MAPS – Position: European Regulatory Lead

Cannabis Law Report

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Founded in 2014, MAPS PBC is a Public Benefit Corporation that prioritizes public benefit over profit. European Regulatory Lead Executive Summary. Key Responsibilities.